Login / Signup

Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.

Diogo MotaTiago Azenha RamaMilton SeveroVanessa Garcia-Larsen
Published in: Allergy (2021)
Keyphrases
  • adverse drug
  • human health
  • emergency department
  • risk assessment
  • climate change